​LEXINGTON, Mass., Feb. 27, 2019 /PRNewswire/ -- Tepha Inc. announced today the initiation of a pilot clinical evaluation of the Company's P4HB regenerative polymer scaffold for the surgical treatment of stress urinary incontinence (SUI).  The study was initiated in Cape Town, South Africa in partnership with the Pelvic Floor Foundation of South Africa ("PFFSA") and the University of Cape Town.  The first procedures were performed by co-principal investigators, Dr. Stephen Jefferyof the University of Cape Town and Professor Jan-Paul Roovers of the Academic Medical Center, Amsterdam, The Netherlands.  The Cape Town SUI study represents the first clinical application of Tepha's P4HB polymer technology in the field of urogynecology.  Based in Lexington, MA, Tepha is the pioneer developer and exclusive supplier of the P4HB polymer for medical applications that include hernia repair, plastic surgery, tendon & ligament repair, and wound closure.

Read More: ​https://www.prnewswire.com/news-releases/tepha-inc-announces-initiation-of-clinical-evaluation-of-p4hb-regenerative-scaffold-for-stress-urinary-incontinence-300803224.html

After winding down its consumer-oriented operations last July, mental health startup Lantern has partnered with larger mental health providers to license its IP. In addition to licensing its IP to Omada Health, Lantern has licensed its tech to Spring Health, Ginger and two others. 

Spring Health, which offers mental health benefits for large employers, provides personalized, clinically proven approaches to mental health care for employees. But Spring Health has always wanted to integrate digital cognitive behavioral therapy into its approach, Spring Health CEO April Koh told TechCrunch.

Spring Health has already offered psychiatry, therapy and self-help tools, but it was wanting to refer people to digital CBT, Koh said.

“There was really only one player that was committed to evidence as deeply as we were and that was Lantern,” she said. “So when the opportunity presented itself, we were thrilled.”

Read More: ​https://techcrunch.com/2019/02/12/mental-health-startup-lantern-will-continue-to-live-through-ip-licensing-deals/